Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
Jaguar Health (NASDAQ:JAGX) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The company's founder, president, and CEO, Lisa Conte, will deliver a virtual presentation and meet with investors during the event.
The conference will be held both virtually and in-person at the Lotte New York Palace. Jaguar Health's on-demand virtual presentation will be available starting at 7:00 AM Eastern on Monday, September 9, 2024. Interested parties can access the presentation through a provided webcast link and register for the conference online.
This event presents an opportunity for Jaguar Health to showcase its developments and engage with potential investors, potentially impacting its stock performance and market visibility.
Jaguar Health (NASDAQ:JAGX) ha annunciato la sua partecipazione alla 26a Conferenza Annuale Mondiale sugli Investimenti H.C. Wainwright, prevista per il 9-11 settembre 2024. La fondatrice, presidente e CEO dell'azienda, Lisa Conte, presenterà una relazione virtuale e incontrerà investitori durante l'evento.
La conferenza si terrà sia virtualmente che di persona presso il Lotte New York Palace. La presentazione virtuale on-demand di Jaguar Health sarà disponibile a partire dalle 7:00 AM Eastern di lunedì 9 settembre 2024. Le parti interessate possono accedere alla presentazione tramite un link webcast fornito e registrarsi per la conferenza online.
Questo evento rappresenta un'opportunità per Jaguar Health di mostrare i suoi sviluppi e interagire con potenziali investitori, con un possibile impatto sulle sue performance azionarie e sulla visibilità nel mercato.
Jaguar Health (NASDAQ:JAGX) ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright, programada para el 9-11 de septiembre de 2024. La fundadora, presidenta y CEO de la empresa, Lisa Conte, realizará una presentación virtual y se reunirá con inversores durante el evento.
La conferencia se llevará a cabo tanto de manera virtual como presencial en el Lotte New York Palace. La presentación virtual a pedido de Jaguar Health estará disponible a partir de las 7:00 AM Eastern del lunes 9 de septiembre de 2024. Las partes interesadas pueden acceder a la presentación a través de un enlace webcast proporcionado y registrarse para la conferencia en línea.
Este evento representa una oportunidad para que Jaguar Health muestre sus desarrollos e interactúe con posibles inversores, lo que podría impactar en su rendimiento accionario y visibilidad en el mercado.
재규어 헬스 (NASDAQ:JAGX)는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 회의는 2024년 9월 9일부터 11일까지 진행됩니다. 회사의 창립자이자 사장 겸 CEO인 리사 콘테가 가상 발표를 진행하고 행사 중 투자자들과 만날 예정입니다.
회의는 롯데 뉴욕 궁전에서 가상 및 대면으로 개최됩니다. 재규어 헬스의 주문형 가상 발표는 2024년 9월 9일 월요일 오전 7시 동부 표준시에부터 이용 가능합니다. 관심 있는 분들은 제공된 웹캐스트 링크를 통해 발표에 접속하고 온라인으로 회의에 등록할 수 있습니다.
이번 이벤트는 재규어 헬스가 개발 내용을 선보이고 잠재 투자자와 교류할 기회를 제공하며, 주식 성과와 시장 가시성에 긍정적인 영향을 미칠 가능성이 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright, prévue du 9 au 11 septembre 2024. La fondatrice, présidente et PDG de l'entreprise, Lisa Conte, fera une présentation virtuelle et rencontrera des investisseurs durant l'événement.
La conférence se déroulera à la fois virtuellement et en personne au Lotte New York Palace. La présentation virtuelle à la demande de Jaguar Health sera disponible à partir de 7h00 AM Eastern le lundi 9 septembre 2024. Les personnes intéressées peuvent accéder à la présentation via un lien de webdiffusion fourni et s'inscrire en ligne à la conférence.
Cette événement représente une opportunité pour Jaguar Health de présenter ses développements et d'interagir avec des investisseurs potentiels, ce qui pourrait influencer sa performance boursière et sa visibilité sur le marché.
Jaguar Health (NASDAQ:JAGX) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt, die für den 9. bis 11. September 2024 geplant ist. Die Gründerin, Präsidentin und CEO des Unternehmens, Lisa Conte, wird eine virtuelle Präsentation halten und während der Veranstaltung mit Investoren sprechen.
Die Konferenz wird sowohl virtuell als auch persönlich im Lotte New York Palace stattfinden. Jagur Healths On-Demand-Virtual-Präsentation wird ab 7:00 Uhr Eastern am Montag, den 9. September 2024 verfügbar sein. Interessierte können über einen bereitgestellten Webinar-Link auf die Präsentation zugreifen und sich online für die Konferenz registrieren.
Diese Veranstaltung bietet Jaguar Health die Gelegenheit, seine Entwicklungen zu präsentieren und mit potenziellen Investoren in Kontakt zu treten, was potenziell Auswirkungen auf die Aktienperformance und die Marktvisibility haben könnte.
- None.
- None.
SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference, which takes place September 9-11, 2024.
Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 26th Annual Global Investment Conference
When: On-demand virtual presentation available starting at 7:00 AM Eastern on Monday, September 9, 2024
Webcast Link: Click here to access the presentation
Where: The conference is taking place virtually and in-person at Lotte New York Palace, 455 Madison Avenue at 50th Street, New York City
To register to attend the conference, click here
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the H.C. Wainwright 26th Annual Global Investment Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
When is Jaguar Health (JAGX) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing Jaguar Health (JAGX) at the H.C. Wainwright conference?
Where is the H.C. Wainwright Global Investment Conference being held?
How can investors access Jaguar Health's (JAGX) presentation at the conference?
What is the significance of Jaguar Health's (JAGX) participation in this investment conference?
